Bayer HealthCare / Press

Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion

Bayer HealthCare announced that EYLEA® (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO). more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.

  • TV Footage

    In this section you can find videos for editorial coverage.

Bayer HealthCare Links

RSS Feed
RSS Feed

Copyright © Bayer HealthCare AG